Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Capital Expenditures (2016 - 2025)

Ocular Therapeutix has reported Capital Expenditures over the past 13 years, most recently at $10.3 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $10.3 million for Q4 2025, up 4984.65% from a year ago — trailing twelve months through Dec 2025 was $12.0 million (up 832.45% YoY), and the annual figure for FY2025 was $12.0 million, up 832.45%.
  • Capital Expenditures for Q4 2025 was $10.3 million at Ocular Therapeutix, up from $1.6 million in the prior quarter.
  • Over the last five years, Capital Expenditures for OCUL hit a ceiling of $10.3 million in Q4 2025 and a floor of -$1.8 million in Q2 2025.
  • Median Capital Expenditures over the past 5 years was $368000.0 (2021), compared with a mean of $1.2 million.
  • Biggest five-year swings in Capital Expenditures: surged 6519.35% in 2023 and later plummeted 343.94% in 2025.
  • Ocular Therapeutix's Capital Expenditures stood at $631000.0 in 2021, then surged by 240.73% to $2.2 million in 2022, then tumbled by 78.65% to $459000.0 in 2023, then plummeted by 55.99% to $202000.0 in 2024, then skyrocketed by 4984.65% to $10.3 million in 2025.
  • The last three reported values for Capital Expenditures were $10.3 million (Q4 2025), $1.6 million (Q3 2025), and -$1.8 million (Q2 2025) per Business Quant data.